<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600912</url>
  </required_header>
  <id_info>
    <org_study_id>SMOF 5178</org_study_id>
    <secondary_id>kli-Lu-spiper 12-2007</secondary_id>
    <nct_id>NCT00600912</nct_id>
  </id_info>
  <brief_title>Influence of of a Lipid Emulsion on Inflammatory Response and Hepatic Function</brief_title>
  <official_title>Inflammatory Response and Hepatic Function in Patients Requiring Parenteral Nutrition: Comparison of a Lipid Emulsion Based ob Soybean Oil, Medium-Chain Triglycerides, Olive Oil and Fish Oil Versus a Lipid Emulsion Based on Olive and Soybean Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Ludwigshafen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum Ludwigshafen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipid emulsions are an essential part of parenteral nutrition, both as a part of energy&#xD;
      supply, and as a source of essential fatty acids. It has been shown that the fatty acid&#xD;
      composition of cell membranes is influenced by the fatty acid profile of dietary lipids, and&#xD;
      may therefore be responsible for modulation of immune response. The aim of this study was to&#xD;
      assess the effects of a new lipid emulsion based ob soybean oil, medium-chain triglycerides,&#xD;
      olive oil and fish oil compared with a lipid emulsion based on olive and soybean oil on the&#xD;
      inflammatory response and hepatic function in postoperative intensive care unit (ICU)&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatty emulsions are an indispensable part of parenteral nutrition, because they deliver&#xD;
      energy and essential fatty acids. Furthermore, lipids are involved in the structure and&#xD;
      function of cell membranes and receptors, modifying gene expression, and modulating the&#xD;
      inflammatory and immune response. In addition, fatty acids are precursors of prostaglandins&#xD;
      and other eicosanoids and have therefore important metabolic functions.A promising substrate&#xD;
      in the development of lipid emulsions can be seen in fish oils containing solutions. With&#xD;
      regard to the current literature, fish oil have a potential benefical influence on the&#xD;
      pathophysiological response to endotoxins and exert important modulations on eicosanoid and&#xD;
      cytokine biology.&#xD;
&#xD;
      However, there are no studies avaibale comparing fish oil containing fatty emulsions to a&#xD;
      lipid emulsion based on olive and soybean oil with regard to inflammatory response and&#xD;
      hepatic function.&#xD;
&#xD;
      Therefore, the aim of this study was to evaluate the effects of a new lipid emulsion based ob&#xD;
      soybean oil, medium-chain triglycerides, olive oil and fish oil compared to a lipid emulsion&#xD;
      based on olive and soybean oil on the inflammatory response and hepatic function in&#xD;
      postoperative intensive care unit (ICU) patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to monitor the leucotriene (LT) LTB5 in patients requiring parenteral nutrition</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic function assessed by measuring alpha-glutathione S-transferase (α-GST), alanin-aminotransferase (ALT),and aspartate-aminotransferase (AST)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Inflammatory Response</condition>
  <condition>Hepatic Function</condition>
  <arm_group>
    <arm_group_label>1-SMOFlipid®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-ClinOleic 20%®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olive and soybean oil-group (n=21)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SMOFlipid®</intervention_name>
    <description>continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.</description>
    <arm_group_label>1-SMOFlipid®</arm_group_label>
    <other_name>SMOFlipid 20%® (Fresenius Kabi Deutschland GmbH,Bad Homburg, Germany)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-ClinOleic 20%®</intervention_name>
    <description>continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.</description>
    <arm_group_label>2-ClinOleic 20%®</arm_group_label>
    <other_name>ClinOleic 20%® (Baxter Deutschland GmbH,Unterschleissheim, Germany)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years&#xD;
&#xD;
          -  Elective operative procedure, and indication for parenteral nutrition over 5&#xD;
             postoperative days&#xD;
&#xD;
          -  ASA I-III&#xD;
&#xD;
          -  Haemoglobin &gt; 10 g/dl&#xD;
&#xD;
          -  Ability and acceptance to agree to the study participation&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver insufficiency (ASAT, ALAT &gt; 40 U/l)&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt; 1.4 mg/dl)&#xD;
&#xD;
          -  Pancreas insufficiency&#xD;
&#xD;
          -  Emergencies&#xD;
&#xD;
          -  Women in child bearing age and missing negative pregnancy test, pregnancy or lactation&#xD;
&#xD;
          -  Diseases from the central nervous system (such as M. Parkinson and multiple sclerosis)&#xD;
&#xD;
          -  Alcohol and drug abuse (including opioid abuse)&#xD;
&#xD;
          -  Acute pulmonary oedema&#xD;
&#xD;
          -  Decompensated cardiac insufficiency&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  Overweight (body mass index &gt; 30 kg/m2&#xD;
&#xD;
          -  Cachexia (body mass index &lt; 18 kg/m2)&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Hypersensitivity to egg, coconut or soy proteins&#xD;
&#xD;
          -  Patients taking chronic corticoids&#xD;
&#xD;
          -  Allergy to any of the study agents&#xD;
&#xD;
          -  Refusal from the patient to participate in the study&#xD;
&#xD;
          -  Participation in another study project&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Swen N. Piper, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Ludwigshafen, Department of Anaesthesiology, Ludwigshafen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen, Department of Anesthesiology and Intensive Care Medicine</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Antébi H, Mansoor O, Ferrier C, Tétégan M, Morvan C, Rangaraj J, Alcindor LG. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr. 2004 May-Jun;28(3):142-8.</citation>
    <PMID>15141405</PMID>
  </reference>
  <reference>
    <citation>Grimm H, Mertes N, Goeters C, Schlotzer E, Mayer K, Grimminger F, Fürst P. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006 Feb;45(1):55-60. Epub 2005 Jul 22.</citation>
    <PMID>16041475</PMID>
  </reference>
  <reference>
    <citation>Adolph M. Lipid emulsions in parenteral nutrition. Ann Nutr Metab. 1999;43(1):1-13. Review.</citation>
    <PMID>10364625</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>December 2, 2009</last_update_submitted>
  <last_update_submitted_qc>December 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Klinikum Ludwigshafen, Dep. of Anesthesiology</name_title>
    <organization>Dr. S. N. Piper</organization>
  </responsible_party>
  <keyword>lipid emulsion</keyword>
  <keyword>fish oil</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>leucotriene LTB5</keyword>
  <keyword>hepatic function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SMOFlipid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

